Weight Gain and Glucose Dysregulation with Second-Generation Antipsychotics and Antidepressants: A Review for Primary Care Physicians

References

• . Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307(5):491–497
   PubMed Web of Science ®Google Scholar
• . Finkelstein E, Khavjou O, Thompson H, . Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012;42(6):563–570
   PubMed Web of Science ®Google Scholar
• . Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66(8):848–856
   PubMed Web of Science ®Google Scholar
• . Verdoux H, Tournier M, Bégaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand. 2010;121(1):4–10
   PubMed Web of Science ®Google Scholar
• . Lieberman J 3rd. The use of antipsychotics in primary care. Primary care companion. J Clin Psychiatry. 2003;5( suppl 3):3–8
   Google Scholar
• . Mark TL, Levit KR, Buck JA. Datapoints: psychotropic drug prescriptions by medical specialty. Psychiatr Serv. 2009;60(9):1167
   PubMedGoogle Scholar
• . Citrome L. Iloperidone: a clinical overview. J Clin Psychiatry. 2011;72( suppl 1):19–23
   PubMedGoogle Scholar
• . Citrome L, Cucchiaro J, Sarma K, . Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27(3):165–176
   PubMed Web of Science ®Google Scholar
• . Kane JM. Lurasidone: a clinical overview. J Clin Psychiatry. 2011;72( suppl 1):24–28
   PubMed Web of Science ®Google Scholar
• . Potkin SG. Asenapine: a clinical overview. J Clin Psychiatry. 2011;72( suppl 1):14–18
   PubMedGoogle Scholar
• . Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf. 2006;29(4):303–319
   PubMedGoogle Scholar
• . Alvarez—Jimenez M, Gonzalez—Blanch C, Crespo—Facorro B, . Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs. 2008; 22(7):547–562
   PubMed Web of Science ®Google Scholar
• . Hasnain M, Vieweg WV, Fredrickson SK, Beatty—Brooks M, Fernandez A, Pandurangi AK. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim Care Diabetes. 2009;3(1):5–15
   PubMedGoogle Scholar
• . McEvoy JP, Lieberman JA, Perkins DO, . Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050–1060
   PubMed Web of Science ®Google Scholar
• . Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19( suppl 1):1–93
   PubMed Web of Science ®Google Scholar
• . Schoemaker J, Stet L, Vrijland P, Naber D, Panagides J, Emsley R. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study [published online ahead of print March 27, 2012]. Pharmacopsychiatry.
   Google Scholar
• . Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21(6):517–535
   PubMed Web of Science ®Google Scholar
• . Lieberman JA, Stroup TS, McEvoy JP, ; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223
   PubMed Web of Science ®Google Scholar
• . Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig. 2011;31(7):455–482
   PubMed Web of Science ®Google Scholar
• . Coppola D, Liu Y, Gopal S, . A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry. 2012;12:26
   PubMed Web of Science ®Google Scholar
• . De Hert M, Mittoux A, He Y, Peuskens J. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci. 2011;261(4):231–239
   PubMedGoogle Scholar
• . Kemp DE, Calabrese JR, Tran QV, Pikalov A, Eudicone JM, Baker RA. Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010;71(9):1138–1144
   PubMed Web of Science ®Google Scholar
• . Osuntokun O, Millen B, Xu WI, . Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics. J Psychopharmacol. 2011;25(5):630–638
   PubMed Web of Science ®Google Scholar
• . Rummel—Kluge C, Komossa K, Schwarz S, . Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2–3):225–233
   PubMed Web of Science ®Google Scholar
• . Kahn RS, Fleischhacker WW, Boter H, ; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–1097
   PubMed Web of Science ®Google Scholar
• . Kryzhanovskaya LA, Xu W, Millen BA, Acharya N, Jen KY, Osuntokun O. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol. 2012;22(2):157–165
   PubMed Web of Science ®Google Scholar
• . Allison DB, Loebel AD, Lombardo I, Romano SJ, Siu CO. Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean? Psychiatry Res. 2009;170(2–3):172–176
   PubMedGoogle Scholar
• . Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry. 2009;70(7):1041–1050
   PubMed Web of Science ®Google Scholar
• . Zheng L, Mack WJ, Dagerman KS, . Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry. 2009;166(5):583–590
   PubMed Web of Science ®Google Scholar
• . Guo Z, L'italien GJ, Jing Y, . A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(5): 1326–1332
   PubMedGoogle Scholar
• . Ulcickas Yood M, Delorenze GN, Quesenberry CP Jr, . Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose? BMC Psychiatry. 2011;11:197
   PubMed Web of Science ®Google Scholar
• . Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab. 2007;33(3):169–175
   PubMed Web of Science ®Google Scholar
• . DuMouchel W, Fram D, Yang X, . Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968–2004). Ann Clin Psychiatry. 2008;20(1):21–31
   PubMedGoogle Scholar
• . Chintoh AF, Mann SW, Lam L, . Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr Res. 2009;108(1–3):127–133
   PubMedGoogle Scholar
• . Hasnain M, Vieweg WV. Acute effects of newer antipsychotic drugs on glucose metabolism. Am J Med. 2008;121(10):e17
   PubMedGoogle Scholar
• . Bai YM, Lin CC, Chen JY, Chen TT, Su TP, Chou P. Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study. J Clin Psychiatry. 2011;72(6):751–756
   PubMedGoogle Scholar
• . Andrade SE, Lo JC, Roblin D, . Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics. 2011;128(6): 1135–1141
   PubMed Web of Science ®Google Scholar
• . Hammerman A, Dreiher J, Klang SH, Munitz H, Cohen AD, Goldfracht M. Antipsychotics and diabetes: an age-related association. Ann Pharmacother. 2008;42(9):1316–1322
   PubMed Web of Science ®Google Scholar
• . Mathys M, Blaszczyk A, Busti A. Incidence of abnormal metabolic parameters and weight gain induced by atypical antipsychotics in elderly patients with dementia. Consult Pharm. 2009;24(3):201–209
   PubMedGoogle Scholar
• . Vieweg WV, Levy JR, Fredrickson SK, . Psychotropic drug considerations in depressed patients with metabolic disturbances. Am J Med. 2008;121(8):647–655
   PubMedGoogle Scholar
• . Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71(10):1259–1272
   PubMed Web of Science ®Google Scholar
• . Wise TN, Perahia DG, Pangallo BA, Losin WG, Wiltse CG. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry. 2006;8(5):269–278
   PubMedGoogle Scholar
• . Tourian KA, Leurent C, Graepel J, Ninan PT. Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry. 2010;12(1):e1–e8
   Google Scholar
• . Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant—what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2012;66(4):356–368
   PubMed Web of Science ®Google Scholar
• . Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry. 2001;62(4):256–260
   PubMed Web of Science ®Google Scholar
• . Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol. 2008;22(8):843–848
   PubMedGoogle Scholar
• . Knol MJ, Geerlings MI, Egberts AC, Gorter KJ, Grobbee DE, Heerdink ER. No increased incidence of diabetes in antidepressant users. Int Clin Psychopharmacol. 2007;22(6):382–386
   PubMedGoogle Scholar
• . Ghaeli P, Shahsavand E, Mesbahi M, Kamkar MZ, Sadeghi M, Dashti—Khavidaki S. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J Clin Psychopharmacol. 2004;24(4):386–388
   PubMed Web of Science ®Google Scholar
• . Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009;166(5):591–598
   PubMed Web of Science ®Google Scholar
• . Chen YC, Shen YC, Hung YJ, Chou CH, Yeh CB, Perng CH. Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. J Affect Disord. 2007;103(1–3):257–261
   PubMedGoogle Scholar
• . Derijks HJ, Meyboom RH, Heerdink ER, . The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol. 2008;64(5): 531–538
   PubMed Web of Science ®Google Scholar
• . Brown LC, Majumdar SR, Johnson JA. Type of antidepressant therapy and risk of type 2 diabetes in people with depression. Diabetes Res Clin Pract. 2008;79(1):61–67
   PubMed Web of Science ®Google Scholar
• . Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006;49(5):837–845
   PubMed Web of Science ®Google Scholar
• . Wagner J, Allen NA, Swalley LM, Melkus GD, Whittemore R. Depression, depression treatment, and insulin sensitivity in adults at risk for type 2 diabetes. Diabetes Res Clin Pract. 2009;86(2):96–103
   PubMedGoogle Scholar
• . Weber—Hamann B, Gilles M, Schilling C, . Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine. J Clin Psychopharmacol. 2008;28(5):581–584
   PubMed Web of Science ®Google Scholar
• . Weber—Hamann B, Gilles M, Lederbogen F, Heuser I, Deuschle M. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry. 2006;67(12):1856–1861
   PubMedGoogle Scholar
• . Maglione M, Maher AR, Hu J, . Off-label use of atypical antipsychotics: an update. http://www.effectivehealthcare.ahrq.gov/ehc/products/150/786/CER43_Off-LabelAntipsychotics_execsumm_20110928.pdf. Accessed June 21, 2012
   Google Scholar
• . Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf. 2011;20(2): 177–184
   PubMed Web of Science ®Google Scholar
• . Eguale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care [published online ahead of print April 16, 2012]. Arch Intern Med.
   Google Scholar
• . De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144–158
   PubMed Web of Science ®Google Scholar
• . Pratt LA, Brody DJ, Gi Q; Centers for Disease Control and Prevention. Antidepressant use in persons aged 12 and over: United States, 2005–2008. NCHS Data Brief. No. 76. October 2011. http://www.cdc.gov/nchs/data/databriefs/db76.htm. Accessed July 15, 2012
   Google Scholar
• . Pagura J, Katz LY, Mojtabai R, Druss BG, Cox B, Sareen J. Antidepressant use in the absence of common mental disorders in the general population. J Clin Psychiatry. 2011;72(4):494–501
   PubMedGoogle Scholar
• . Mojtabai R, Olfson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Aff (Millwood). 2011;30(8):1434–1442
   PubMed Web of Science ®Google Scholar
• . Lee E, Teschemaker AR, Johann—Liang R, . Off-label prescribing patterns of antidepressants in children and adolescents. Pharmacoepidemiol Drug Saf. 2012;21(2):137–144
   PubMed Web of Science ®Google Scholar
• . Leucht S, Komossa K, Rummel—Kluge C, . A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2): 152–163
   PubMed Web of Science ®Google Scholar
• . Komossa K, Rummel—Kluge C, Hunger H, . Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(3):CD006654
   Google Scholar
• . Cipriani A, Barbui C, Salanti G, . Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378(9799):1306–1315
   PubMed Web of Science ®Google Scholar
• . Gartlehner G, Hansen RA, Morgan LC, . Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review. http://www.ncbi.nlm.nih.gov/books/NBK83442/pdf/TOC.pdf. Accessed June 21, 2012
   Google Scholar
• . Ness—Abramof R, Apovian CM. Drug-induced weight gain. Drugs Today (Barc). 2005;41(8):547–555
   PubMedGoogle Scholar
• . Stevenson FA, Barry CA, Britten N, Barber N, Bradley CP. Doctor-patient communication about drugs: the evidence for shared decision making. Soc Sci Med. 2000;50(6):829–840
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601
   PubMed Web of Science ®Google Scholar
• . Meisinger C, Doring A, Thorand B, Heier M, Lowel H. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study. Am J Clin Nutr. 2006;84(3):483–489
   PubMed Web of Science ®Google Scholar
• . Grundy SM, Cleeman JI, Daniels SR, . Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–2752
   PubMed Web of Science ®Google Scholar
• . International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/MetSyndrome_FINAL.pdf. Accessed June 21, 2012
   Google Scholar
• . Centers for Disease Control and Prevention. National Center for Health Statistics. 2000 CDC growth charts: United States. http://www.cdc.gov/growthcharts/. Accessed June 21, 2012
   Google Scholar
• . de Leon J, Susce MT, Johnson M, . A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res. 2007;92(1–3): 95–102
   PubMed Web of Science ®Google Scholar
• . Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70(1):1–17
   PubMed Web of Science ®Google Scholar
• . Birkenaes AB, Birkeland KI, Engh JA . Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol. 2008;28(2):132–137
   PubMedGoogle Scholar
• . Ahmed M, Griffn D, O'Toole R, McDonald C. Clozapine-induced severe mixed hyperlipidemia: a case report. Gen Hosp Psychiatry. 2009;31(1):93–96
   PubMedGoogle Scholar
• . Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001;21(4):369–374
   PubMedGoogle Scholar
• . Morrato EH, Druss B, Hartung DM, . Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry. 2010;67(1):17–24
   PubMed Web of Science ®Google Scholar
• . Mackin P, Bishop DR, Watkinson HM. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry. 2007;7:28
   PubMed Web of Science ®Google Scholar
• . Hasnain M, Vieweg VW. Do we truly appreciate how difficult it is for patients with schizophrenia to adapt a healthy lifestyle? Acta Psychiatr Scand. 2011;123(6):409–410
   PubMedGoogle Scholar
• . Lambert TJ, Newcomer JW. Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Med J Aust. 2009;190( 4 suppl):S39–S42
   PubMed Web of Science ®Google Scholar
• . Vieweg WV, Hasnain M, Pandurangi AK. Coordinated medical and psychiatric care in schizophrenia. Am J Med. 2012;125(3):219–220
   PubMedGoogle Scholar
• . Pearson TA, Blair SN, Daniels SR, . AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106(3):388–391
   PubMed Web of Science ®Google Scholar
• . Kluge M, Schuld A, Himmerich H, . Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol. 2007;27(6):662–666
   PubMed Web of Science ®Google Scholar
• . Laddu D, Dow C, Hingle M, Thomson C, Going S. A review of evidence-based strategies to treat obesity in adults. Nutr Clin Pract. 2011;26(5):512–525
   PubMed Web of Science ®Google Scholar
• . Ratner RE; Diabetes Prevention Program. An update on the Diabetes Prevention Program. Endocr Pract. 2006;12( suppl 1):20–24
   PubMedGoogle Scholar
• . Alvarez—Jiménez M, Hetrick SE, González—Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008;193(2):101–107
   PubMed Web of Science ®Google Scholar
• . National Heart, Lung, and Blood Institute. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf. Accessed June 21, 2012
   Google Scholar
• . Dording CM, Mischoulon D, Petersen TJ, . The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry. 2002;14(3):143–147
   PubMedGoogle Scholar
• . Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther. 2005;27(12):1930–1941
   PubMed Web of Science ®Google Scholar
• . Montes JM, Rodriguez JL, Balbo E, . Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):383–388
   PubMedGoogle Scholar
• . De Hert M, Hanssens L, van Winkel R, . A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull. 2007;33(3):823–830
   PubMedGoogle Scholar
• . Kim SH, Ivanova O, Abbasi FA, Lamendola CA, Reaven GM, Glick ID. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. J Clin Psychopharmacol. 2007;27(4):365–368
   PubMedGoogle Scholar
• . Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology. 2010;35(7):1520–1530
   PubMed Web of Science ®Google Scholar
• . Ellinger LK, Ipema HJ, Stachnik JM. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. Ann Pharmacother. 2010;44(4): 668–679
   PubMedGoogle Scholar
• . Narula PK, Rehan HS, Unni KE, Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res. 2010;118(1–3):218–223
   PubMedGoogle Scholar
• . Hasnain M, Vieweg WV, Fredrickson SK. Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions. CNS Drugs. 2010;24(3):193–206
   PubMedGoogle Scholar
• . Hasnain M, Fredrickson SK, Vieweg WV. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs. J Psychopharmacol. 2011;25(6): 715–721
   PubMedGoogle Scholar
• . Wang M, Tong JH, Zhu G, Liang GM, Yan HF, Wang XZ. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. Schizophr Res. 2012;138(1):54–57
   PubMed Web of Science ®Google Scholar
• . ; Diabetes Prevention Program Research GroupKnowler WC, Fowler SE, Hamman RF, 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–1686
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Davidson MB, DeFronzo RA, . Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30(3):753–759
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration website. http://www.accessdata.fda.gov/scripts/cder/drugsatfda. Accessed June 21, 2012
   Google Scholar
• . American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33( suppl 1):S62–S69
   PubMed Web of Science ®Google Scholar